<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>277762</rcn>
  <id>101221066</id>
  <acronym>PriME</acronym>
  <teaser>Efficient anticancer immune effects are a prime medical discovery of this century. Molecular alarms drive such immune responses, signaling priming and effector cells to action. Several approaches are studied or clinically used to initiate or support such action. Yet, the...</teaser>
  <objective>Efficient anticancer immune effects are a prime medical discovery of this century. Molecular alarms drive such immune responses, signaling priming and effector cells to action. Several approaches are studied or clinically used to initiate or support such action. Yet, the perhaps evolutionary old and most conserved mechanism has been mostly off the map so far: reactive oxygen species (Physical-technical applications extend into medicine for diagnostics and also therapies, such as: cancer treatment. Tumor cells present various receptors on the cell surface, and immune cells can interact with these receptors to decide whether a cell should be eliminated or not. Therapies or other external influences can change the spectrum of the presented receptors and thus the interaction, aiming to stimulate an immune response. Once a tumor cell gets identified as harmful, an immune response is initiated to recruit cytotoxic T cells and other adaptive immune cells to reduce tumor growth. Physical plasmas are therapeutic and have antimicrobial efficacy and cancer-killing effects. Plasmas can be generated to operate at low temperatures, which enables them for medical applications, and produced reactive oxygen and nitrogen species (ROS) mainly induce biomedical effects. In tumor cells, plasma treatment leads to redox stress, followed by altered surface marker expression, which has immune-stimulating properties. However, ROS are not absent when the tumor cell dies, and further ROS-mediated mechanisms, such as oxidation of released biomolecules, continue. I hypothesize that immune-stimulatory properties of plasma are combinatory effects of molecular changes and biomolecule oxidation, suggesting that a standardized plasma treatment with maximized ROS, more precisely radical production, optimizes biomolecule oxidation and immunological consequences. My vision is to establish a novel approach to plasma-treated cancers by oxidizing cancer lysates with plasma for use as a therapeutic vaccine.</objective>
  <title>Starting Grant</title>
  <keywords>CAP; free radical chemistry; gas plasma technology; low-temperature plasma; mass spectrometry; non-thermal plasma; oncology; plasma medicine; ROS; redox chemistry</keywords>
  <totalCost>1499892</totalCost>
  <ecMaxContribution>1499892</ecMaxContribution>
  <startDate>2026-02-01</startDate>
  <endDate>2031-01-31</endDate>
  <ecSignatureDate>2025-10-06</ecSignatureDate>
  <duration>60</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101221066</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate readOnly="true">2025-10-17 11:56:37</contentCreationDate>
  <contentUpdateDate>2025-11-26 11:16:09</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-11-26 11:16:12</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>57053</rcn>
        <title>ERC-2025-STG</title>
        <identifier>ERC-2025-STG</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>57053</rcn>
        <title>ERC-2025-STG</title>
        <identifier>ERC-2025-STG</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="1499892" terminated="false" sme="false" netEcContribution="1499892" totalCost="1499892" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>2192624</rcn>
        <id>998962746</id>
        <vatNumber>DE137584418</vatNumber>
        <legalName>LEIBNIZ-INSTITUT FUR PLASMAFORSCHUNG UND TECHNOLOGIE EV</legalName>
        <shortName>INP GREIFSWALD</shortName>
        <address>
          <street>FELIX HAUSDORFF STRASSE 2</street>
          <city>Greifswald</city>
          <postalCode>17489</postalCode>
          <country>DE</country>
          <url>https://www.inp-greifswald.de</url>
          <geolocation>54.091964700000005,13.40194120163702</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/REC</code>
              <title>Research Organisations</title>
              <displayCode readOnly="true">/Research Organisations</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Vorpommern-Greifswald</name>
              <rcn>1465454</rcn>
              <nutsCode>DE80N</nutsCode>
              <parents>
                <region>
                  <name>Mecklenburg-Vorpommern</name>
                  <rcn>221806632</rcn>
                  <nutsCode>DE80</nutsCode>
                  <parents>
                    <region>
                      <name>Mecklenburg-Vorpommern</name>
                      <rcn>221809192</rcn>
                      <nutsCode>DE8</nutsCode>
                      <parents>
                        <region>
                          <name>Germany</name>
                          <rcn>221940264</rcn>
                          <nutsCode>DE</nutsCode>
                          <euCode>DE</euCode>
                          <isoCode>DE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Germany</name>
              <rcn>221940264</rcn>
              <nutsCode>DE</nutsCode>
              <euCode>DE</euCode>
              <isoCode>DE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>709265</rcn>
        <id>HORIZON_ERC-2025-STG</id>
        <code>ERC-2025-STG</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC STARTING GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/23/53/373/1131</code>
        <title>electrolysis</title>
        <displayCode readOnly="true">/natural sciences/chemical sciences/electrochemistry/electrolysis</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997</code>
        <title>biomolecules</title>
        <displayCode readOnly="true">/natural sciences/biological sciences/biochemistry/biomolecules</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155</code>
        <title>immunology</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/immunology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159/653/1439</code>
        <title>vaccines</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drugs/vaccines</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC</code>
        <title>HORIZON ERC Grants</title>
        <description>HORIZON ERC Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
